Methylphenidate Exposure in Pregnancy May Lead to Congenital Heart Defects
Congenital malformations occurred in 45.9 per 1000 infants after methylphenidate intrauterine exposure.
HealthDay News — Intrauterine exposure to methylphenidate is associated with a small increase in the risk of cardiac malformations, according to a study published in JAMA Psychiatry.
Krista F. Huybrechts, PhD, from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the risk of congenital malformations associated with intrauterine exposure to stimulants. Data were included for 1,813,894 publicly-insured pregnancies in the United States and 2,560,069 singleton pregnancies ending in live births in the 5 Nordic countries.
The researchers found that congenital malformations occurred in 35.0 per 1000 infants not exposed to stimulants, compared with 45.9 and 45.4 per 1000 infants for methylphenidate and amphetamines, respectively, in the US data.
The risks were 12.7, 18.8, and 15.4, respectively, per 1000 infants for cardiac malformations. The adjusted relative risks were 1.11 (95% CI, 0.91 to 1.35) and 1.28 (95% CI, 0.94 to 1.74) for any malformation and cardiac malformations, respectively, for methylphenidate. The risks were not increased for amphetamines. Using the Nordic data, the analyses for methylphenidate yielded a relative risk of 1.28 (95% CI, 0.83 to 1.97) for cardiac malformations, resulting in a pooled estimate of 1.28 (95% CI, 1.00 to 1.64).
"This information is important when weighing the risks and benefits of alternative treatment strategies for attention-deficit/hyperactivity disorder in women of reproductive age and during early pregnancy," the authors write.
Huybrechts KF, Broms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium [published online December 13, 2017]. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2017.3644